Skip to content
value.today

Marpai, Inc.

MRAI
$14 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
$18 M
For year ending December-2025
Net income
$-17 M
-91.5% margin
SEC filing
Employees
107
As of December 31, 2025
SEC filing

Marpai, Inc. in brief

Marpai, Inc. is a listed company in the Healthcare sector, based in Tampa, Florida, USA. Its last known market value was $14 M (January 2024); there is no current figure. In the year to December 2025 it had sales of $18 M and a net loss of $17 M. It employs about 107 people. Its largest product and service lines by sales in 2025 were Third party administrator services (100%).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Marpai, Inc.

We are a technology platform company which operates subsidiaries that provide Third Party Administrator, Pharmacy Benefit Management, and value-oriented health plan services to employers that directly pay for employee health benefits. Our mission is to positively change healthcare for the benefit of (i) our Clients who are self-insured employers that pay for their employees’ healthcare benefits and engage us to administer the latter’s healthcare claims, and we refer to them as our “Clients”, (ii) employees and their family members who receive these healthcare benefits from our Clients, and we refer to them as our “Members”, and (iii) healthcare providers including, doctors, doctor groups, hospitals, clinics, and any other entities providing healthcare services or products, and we refer to them as the “Providers.” We provide affordable, intelligent, healthcare programs for self-insured employers in the U.S. We provide administrative services, and act as TPA to self-insured employers who provide healthcare benefits to their employees. Most of our Clients are small and medium-sized companies as well as local government entities.

From the company's annual report filed with the US SEC: read the report

Marpai, Inc. timeline

3 events, 2021–2023
  1. 2021
  2. 🔔
    · approximate
    Initial public offering
  3. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  4. 2023
  5. 💰
    Record revenue of $37 million
    FY2023, the highest of the 5 years on record.

Events of Marpai, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$5 M$9 M$14 M$18 M20232024

World rank over time

▼ down 374 places since 2022
2022-12-25: #29818#29,81820222023-07-30: #30809#30,80920232024-01-05: #30192#30,1922024

Rank in USA: #5,354 (Dec 2022) · #5,344 (Jul 2023) · #4,446 (Jan 2024)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
-98.1%
Operating margin
-74.9%
Return on equity
—
Liabilities / assets
398.8%
Net debt
$19M
Revenue growth
-35.7%
R&D / revenue
0.1%
Revenue per employee
$169 K
Profit per employee
$-155 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2020: revenue —, net income $-4M—FY20Fiscal year ending Dec 2021: revenue $14M, net income $-16M$14MFY21Fiscal year ending Dec 2022: revenue $24M, net income $-26M$24MFY22Fiscal year ending Dec 2023: revenue $37M, net income $-29M$37MFY23Fiscal year ending Dec 2024: revenue $28M, net income $-22M$28MFY24Fiscal year ending Dec 2025: revenue $18M, net income $-17M$18MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$18M-35.7%$-14M$-17M-91.5%
Dec 2024$28M-24.2%$-22M$-22M-78.4%
Dec 2023$37M+52.7%$-28M$-29M-77.4%
Dec 2022$24M+71.0%$-27M$-26M-108.8%
Dec 2021$14M—$-16M$-16M-112.3%
Dec 2020——$-3M$-4M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-7M——$-0.95—
Dec 2024$-15M——$-1.92—
Dec 2023$-16M——$-4.14—
Dec 2022$-35M$0M$-36M$-5.23—
Dec 2021$-11M$0M$-11M$-1.59—
Dec 2020$-2M$0M$-2M$-1.60—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$17M
Net income, trailing 12 months
$-17M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $7M, net income $-1M$7MDec ’24Three months to Mar 2025: revenue $5M, net income $-3M$5MMar ’25Three months to Jun 2025: revenue $5M, net income $-4M$5MJun ’25Three months to Sep 2025: revenue $4M, net income $-3M$4MSep ’25Three months to Dec 2025 (from the annual report): revenue $4M, net income $-6M$4MDec ’25Three months to Mar 2026: revenue $4M, net income $-3M$4MMar ’26Three months to Jun 2026: revenue $4M, net income $-5M$4MJun ’26Three months to Sep 2026: revenue $4M, net income $-3M$4MSep ’26

Latest quarter to Sep 2026: revenue $4M (+9.4% on a year earlier), net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Marpai, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$18 M
Operating income
$-14 M
Net income
$-17 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$11 M
Total liabilities
$43 M
Total equity
$-33 M

As of December-2025

Insider trading at Marpai, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$3 K
2 purchases, 2 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$3 K
open market only
Insiders on file
18
since
$1.5 M-$225 K$0Nov 2023: bought $361 K (2 trades), sold $0 (0 trades)Nov 23Dec 2023: bought $416 K (3 trades), sold $0 (0 trades)Jan 2024: bought $1.2 M (3 trades), sold $0 (0 trades)Jan 24Mar 2024: bought $1.5 M (1 trades), sold $0 (0 trades)May 2024: bought $61 K (6 trades), sold $115 K (3 trades)MayAug 2024: bought $649 K (1 trades), sold $0 (0 trades)Dec 2024: bought $142 K (3 trades), sold $0 (0 trades)DecJul 2025: bought $501 K (2 trades), sold $0 (0 trades)Aug 2025: bought $0 (0 trades), sold $225 K (10 trades)AugSep 2025: bought $1.2 M (2 trades), sold $0 (0 trades)Oct 2025: bought $0 (0 trades), sold $46 K (2 trades)OctNov 2025: bought $150 K (3 trades), sold $0 (0 trades)May 2026: bought $3 K (1 trades), sold $0 (0 trades)MayJun 2026: bought $682 (1 trades), sold $0 (0 trades)
Bought (open market)Sold (open market)Hover a month for the totals
Marpai, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Steve Andrew JohnsonChief Financial OfficerBuy+1,100$0.620$6821.02 MForm 4
filed Colleen DiClaudioDirectorGrant or award10b5-1 plan+125,000——267,500Form 4
filed Steve Andrew JohnsonChief Financial OfficerGrant or award+125,000——1.02 MForm 4
filed Damien LamendolaChief Executive Officer, Director, 10% ownerGrant or award+300,000——1.65 MForm 4
filed Robert M. PonsDirectorGrant or award+100,000——484,200Form 4
filed Yaron EitanDirectorGrant or award+175,000——1.22 MForm 4
filed Sagiv ShivDirectorGrant or award10b5-1 plan+125,000——613,667Form 4
filed Jennifer Rosario CalabreseDirectorGrant or award10b5-1 plan+100,000——225,000Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Marpai, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Stock splits: 1-for-4 reverse split ; 4.556-for-1 split

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Marpai, Inc. scorecard#

Passes 1 of the 12 checks that could be worked out: strongest in profitability (1 of 4), weakest in growth (0 of 5). Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth0 of 5
    • ✗Revenue grew in the newest year-35.8%Revenue down 35.8% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-9.4%-9.4% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-9.4%-9.4% a year against Healthcare's median of 8.5% (549 companies).
    • ✗Earnings per share grew in the newest year-0.95 vs -1.92Diluted EPS -0.95 in fiscal 2025 against -1.92 the year before (report's currency).
    • ✗Net income higher than five years earlier-$17 M-$17 M in fiscal 2025 against -$4 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability1 of 4
    • ✗Profitable in the newest year-$17 MNet income -$17 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-74.9%-74.9% against Healthcare's median of -7.7% (674 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-74.9%-74.9% in fiscal 2025 against -110.8% in 2022.
  • Financial health0 of 2
    • ✗Short-term assets cover short-term liabilities0.4×Current ratio 0.40 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year50.9%Diluted shares up 50.9% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Healthcare, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Marpai, Inc.'s statements, beside the median of Healthcare.

Marpai, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-74.9%-7.7%
Net margin-91.5%-8.1%
Revenue growth, 3 years a year-9.4%8.5%
Revenue growth-35.8%10.2%

3of 8on the Piotroski tests of financial strength

  • Revenue fell 35.8% against the year before.
  • Net loss of $17 million, the 6th loss-making year in a row.
  • The share count rose 50.9% in the year.
  • Shareholders' equity is negative: -$33 million.

Marpai, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Marpai, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Revenue182837r2414—
Research and development0.00.01.3r3.71.71.8
Selling and marketing1.11.86.6r6.95.00.0
General and administrative111319r128.11.5
Total costs and expenses325065r51303.4
Operating income−14−22−28r−27−16−3.4
Interest expense and finance costs3.22.71.5r0.30.40.5
Other non-operating income (expense)—0.40.5r0.20.20.0
Income before tax−17−23−29r−27−16−3.9
Income tax—−1.2−0.3r−0.5−0.2—
Net income including minority interests——−29−26−16−3.9
Net income attributable to shareholders−17−22−29r−26−16−3.9
Earnings per share, basic-0.95-1.92-4.14-5.23r-1.59-1.60
Earnings per share, diluted-0.95-1.92-4.14-5.23r-1.59-1.60
Shares, weighted average (basic)17127.05.1r102.4
Shares, weighted average (diluted)17127.05.1r102.4
Balance sheet
Cash and cash equivalents0.10.81.1r14191.8
Receivables0.70.81.1r1.40.2—
Other current assets0.40.80.9r1.60.70.3
Current assets101217r27272.2
Property, plant and equipment000.6r1.50.90.2
Right-of-use (leased) assets0.20.32.4r3.82.00.3
Goodwill——3.0r3.0r2.4—
Other intangible assets0.10.45.2r6.35.5—
Total assets111332r50446.5
Accounts payable3.73.14.6r1.51.10.2
Debt due within a year8.0—————
Current liabilities261921r17112.6
Long-term debt11—————
Lease liabilities (non-current)0.50.83.7r4.81.30.3
Total liabilities434145r441410
Retained earnings−115−99−77−48−22−5.5
Shareholders' equity−33−28−13r6.1r30−3.5
Total liabilities and equity111332r50446.5
Shares outstanding24148.05.3r200.1
Cash-flow statement
Depreciation and amortization0.42.33.93.52.00.1
Share-based compensation3.63.22.1r3.11.21.0
Cash from operating activities−7.5−15−16r−35−11−1.9
Capital expenditure———−0.4−0.3−0.0
Intangible assets bought————−0.0—
Cash from investing activities0.50.21.0r329.6−0.6
Shares issued7.04.76.4r———
Cash from financing activities6.7115.1r0.0254.1
Change in cash——−9.6−2.8241.6
Report10-K10-K10-K10-K10-K/A10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Marpai, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Third party administrator services$18 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Marpai, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$1.2 M
Other top executives, average
$1.3 M
the CEO earned 1× this
$100 invested is now
$19
Marpai, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Chief executive$1.2 M$1.2 M$1.3 M$19
2024Chief executive$362 K$712 K$514 K$25

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Marpai, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 3 · Material agreement 15 · New debt 3 · Unregistered share sale 10 · Bylaws or fiscal year changed 2 · Shareholder vote 1 · Results announced 6

Marpai, Inc.: events reported to the SEC
FiledWhat happenedFiling
Material agreementUnregistered share saleBylaws or fiscal year changed8-K
Material agreement8-K
Material agreement8-K
Material agreementNew debt8-K
Material agreementNew debt8-K
Directors and officers8-K
Material agreementUnregistered share sale8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Bylaws or fiscal year changed8-K
Material agreementUnregistered share sale8-K
Material agreementUnregistered share sale8-K
Directors and officers8-K
Shareholder vote8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Material agreement8-K
Material agreementNew debtUnregistered share sale8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Jul 31, 2026

How Marpai, Inc. compares in Healthcare

  • Revenue$18 M · higher than 26% of 1,795
  • Net margin-98.1% · higher than 17% of 1,485
  • Revenue growth-35.8% · higher than 13% of 1,003
CompanyMarket capP/ENet marginRev. growth
Marpai, Inc.🇺🇸$14 M—-98.1%-35.8%
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
UnitedHealth Group Incorporated🇺🇸$367.7 B23.1×3.5%+11.8%
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 5, 2024 (last known)
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 16, 2026

Figures from SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Marpai, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Marpai, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Marpai, Inc.? Suggest a correction